Diagnostics Firms Qiagen, BioMerieux Said to Explore Tie-Up
(Bloomberg) -- Molecular testing firm Qiagen NV and French rival BioMerieux are exploring a potential combination that would unite two of Europe's biggest medical diagnostics providers, people with knowledge of the matter said.Â
The two companies have been studying the merits of a merger, said the people, who asked not to be identified because the discussions are private.Â
Shares of Qiagen, which has a market capitalization of about 11.2 billion euros ($13 billion), jumped as much as 4.8% in Frankfurt trading Wednesday to hit the highest level in more than two decades. BioMerieux shares rose as much as 6.1%, the biggest intraday gain in two months. They were up 1.3% at 1:08 p.m. in Paris, valuing the company at about 13.3 billion euros.
Qiagen's potential move comes as it weighs options for its future after Thermo Fisher Scientific Inc. abandoned plans for a $12 billion takeover last year. Since then, the rollout of vaccination programs has led to reduced levels of testing for Covid-19. In July, Qiagen revised earnings forecasts downward, citing fewer coronavirus tests.
Deliberations are at an early stage, and there's no certainty they will result in a transaction, according to the people. A possible stumbling block in negotiations could be how much France's Merieux family, the biggest holder of BioMerieux, would own in a combined entity, the people said. Qiagen could also attract interest from other suitors, they said.Â
The company became the subject of takeover interest in February, when U.S. diagnostics firm and fellow coronavirus testmaker Quidel Corp. explored a combination, Bloomberg News reported. A deal did not materialize.
Last month, the Betaville blog reported rumors about renewed interest in a deal for Qiagen involving an unknown company. A representative for Qiagen declined to comment, while a spokesperson for BioMerieux couldn't immediately comment.
Qiagen is led by Chief Executive Officer Thierry Bernard, a former BioMerieux executive. It sells products for food and forensic testing and has also been manufacturer of Covid-19 tests, tapping a lucrative market for diagnostics companies.
Paris-listed BioMerieux specializes in so-called in vitro diagnostics, tests performed on blood and tissue. The company has a presence in 44 countries and posted revenue of 3.1 billion euros in 2020, more than 90% of which was generated outside France, according to its website.
Health-care companies have been a key driver of the ongoing boom in global mergers and acquisitions. Transactions valued at $486 billion have been announced in the sector this year, a 77% increase on the same period in 2020, according to data compiled by Bloomberg. These include one of the year's biggest deals, the more than $30 billion leveraged buyout of Medline Industries Inc.Â
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.